Research programme: antibody therapeutics - Y-Biologics
Alternative Names: AR 003; YBL 002; YBL 005Latest Information Update: 28 Apr 2021
Price :
$50 *
At a glance
- Originator Y-Biologics
- Developer Ahn-Gook Pharmaceutical; Y-Biologics
- Class Antibodies; Biobetters
- Mechanism of Action Immunomodulators; Programmed cell death 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer; Multiple sclerosis
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Cancer in South Korea (Parenteral)
- 28 Apr 2021 No recent reports of development identified for research development in Autoimmune-disorders in South Korea (Parenteral)
- 28 Apr 2021 No recent reports of development identified for research development in Multiple-sclerosis in South Korea (Parenteral)